Listen
REVLIMID
-
Opinions on drugs -
Posted on
Jun 06 2012
- Updated on
Jun 23 2012
Reason for request
Own-initiative opinion by the transparency Committee for re assessment of Actual Benefit (AB) and Improvement of Actual Benefit (IAB) in the indication “REVLIMID in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy” in accordance with Article R 163-21 of the social security code.
-
Clinical Benefit
| Substantial |
The actual benefit offered by REVLIMID remains substantial. |
Clinical Added Value
| moderate |
The Committee considers that, based on the currently available data, REVLIMID retains the moderate IAB (level III) assigned to it in 2007, in relation to the management of patients with multiple myeloma and who have already received at least one treatment. |
Documents
English version
Contact Us
Évaluation des médicaments
